Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 5 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar pleached (76.17) Submitted: 11/27/2006 2:16:12 AM : Outperform Start Price: $8.76 EXEL Score: -47.38

Deep pipeline with some close to market.

Featured Broker Partners


Advertisement